BLSM Stock — BlossomHill Therapeutics, Inc. Common Stock

BlossomHill Therapeutics, Inc. Common Stock (BLSM)

Updated October 16, 2026.

BLSM is a Stock. Total return is -12.9% over the past 0.2 years, 12.5 points behind SPY at -0.4%.

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for cancer treatment, with a pipeline that includes an OMNI-EGFR inhibitor for advanced lung cancer and a macrocyclic CLK inhibitor being evaluated for leukemia and myelodysplastic syndrome. The company does not currently distribute dividends. This security may appeal to investors seeking exposure to early-stage oncology drug development, though investors should note the typical risks associated with clinical-stage biotechnology companies.

BLSM performance versus SPY

Price and return data through 2026-10-16.

Total return is -12.9% over the past 0.2 years, 12.5 points behind SPY at -0.4%.

BLSM key facts

Asset type

Stock

Asset class

Equity

Inception date

08/06/2026

Distribution frequency

None

Last close

$13.94 (as of 2026-10-16)

Market cap

$443,081,631

Average volume

293107.0

Payout ratio

0.0%

EPS

$-4.65

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BLSM risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider BLSM — and who may not

It is a weaker fit for investors who need monthly cash flow (BLSM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BLSM

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions